Cramer said that Alexion's primary drug, Soliris, is the gift that keeps on giving. It currently treats ultra-rare blood conditions to the tune of $1.5 billion in sales, but is also in testing to treat numerous other conditions which could add another $2.5 billion in sales. Shares of Alexion are down 19 points from their highs after a disappointing quarter in October and the company receiving an FDA warning letter last week.
Cramer said he's not worried about the quarter because the analysts clearly got ahead of themselves, and the warning letter simply means the company will need to refine how it manufactures Soliris a little further. Trading at just 28 times earnings with a 33% growth rate, Cramer said that Alexion remains a bargain.
Then there's BioMarin, a company with a $7.7 billion market cap but no earnings. Cramer said this company makes enzyme replacement therapies to treat a host of rare genetic diseases. Like Alexion, it has a robust pipeline of new drugs and new indications for its existing stable. Shares of BioMarin are just off their highs and Cramer said he remains a buyer of this biotech, too.
Investors looking for this quarter's top performers might want to take a look at last quarter's top performers, said Cramer, who ran through the top 10 stocks from the
tops the list and is likely to have an encore performance this quarter as its original content and other media deals continue to make it must-have entertainment.
Cramer said the next three winners from last quarter --
-- aren't likely to do well this quarter as they've run out of gas.
He was more upbeat on
, however, because consolidation has made it one of only three DRAM memory suppliers, down from seven just two years ago.
In the health care group, Cramer said
both remain favorites.
are both inexpensive.
Finally, there's grocer
, a stock that was up 45% last quarter as that company continues to make a comeback against
. At 11 times earnings, Cramer said, Safeway is a steal.
In the Lightning Round, Cramer was bullish on
Alaska Air Group
US Airways Group
Which Is Better?
Sometimes the right question to ask is not "which is the better stock," but "which is the better stock... for me." That was the question Cramer was pondering over the weekend after an oil spill made him question whether pipeline operators such as
(ENB - Get Report)
are better or worse than a company such as
American Water Works
(AWK - Get Report)
, whose CEO appeared on "Mad Money" last week. Both transport liquids via pipes, noted Cramer, but they appeal to different investors.
Cramer said investors looking for less risk should certainly chose American Water Works. The company has a lot of room to expand, but when its pipes burst the environmental effects are small.
Meanwhile, those looking for more growth should consider Enbridge, the lowest-priced pipeline operator and the largest in the country. Enbridge predicts $35 billion in new investments coming, said Cramer, and the company sports a 2.7% dividend. Enbridge also has terrific earnings visibility.
No Huddle Offense
In his "No Huddle Offense" segment, Cramer took a quick look at some of last quarter's
losers. He said the declines in
Cliffs Natural Resources
continue to weigh on the averages, but those of
have presented buying opportunities.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC
-- Written by Scott Rutt in Washington, D.C.
To email Scott about this article, click here:
Follow Scott on Twitter
or get updates on Facebook,